ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CLIN Clinigen Group Plc

925.00
0.00 (0.00%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Clinigen Group Plc LSE:CLIN London Ordinary Share GB00B89J2419 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 925.00 924.50 925.00 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Clinigen Group plc Annual Report and Accounts and notice of AGM (2915O)

03/10/2019 7:00am

UK Regulatory


Clinigen (LSE:CLIN)
Historical Stock Chart


From Apr 2019 to Apr 2024

Click Here for more Clinigen Charts.

TIDMCLIN

RNS Number : 2915O

Clinigen Group plc

03 October 2019

3 October 2019

Posting of Annual Report and Accounts and notice of AGM

Clinigen Group plc (AIM: CLIN, 'Clinigen' or 'the Group'), the global pharmaceuticals and services group, announces that its Annual Report and Accounts for the year ended 30 June 2019 is now available on the Group's website at www.clinigengroup.com.

Copies of the Annual Report and Accounts will be also posted to shareholders later today.

The Group will hold its Annual General Meeting ('AGM') on 26 November 2019 at 10.00am at Instinctif Partners' offices, 65 Gresham Street, London EC2V 7NQ. Shaun Chilton, Group Chief Executive Officer, will give a presentation at the AGM. The slides will be made available on the Group's website after the meeting. No new material information will be provided.

- Ends -

Contact Details

 
 Clinigen Group plc                             Tel: +44 (0) 1283 495 
                                                 010 
 Peter Allen, Chairman 
  Matt Parrish, Head of Investor Relations 
 
 Numis Securities Limited - Nominated Adviser   Tel: +44 (0) 20 7260 1000 
  & Joint Broker 
 James Black / Freddie Barnfield / Freddie 
  Naylor-Leyland 
 
 RBC Capital Markets - Joint Broker             Tel: +44 (0) 20 7653 4000 
 Marcus Jackson / Elliot Thomas 
 
 Instinctif Partners                            Tel: +44 (0) 20 7457 2020 
 Adrian Duffield / Melanie Toyne-Sewell / 
  Rozi Morris                                   Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. The Group has sites in North America, Europe, Africa and Asia Pacific.

Clinigen now has over 1,100 employees across five continents in 14 countries, with supply and distribution hubs and operational centres of excellence in key long-term growth regions. The Group works with 22 of the top 25 pharmaceutical companies; interacting with over 15,000 registered users across over 100 countries, shipping approximately 6.4 million units in the year.

For more information on Clinigen, please visit www.clinigengroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ACSCKDDQABDKBKK

(END) Dow Jones Newswires

October 03, 2019 02:00 ET (06:00 GMT)

1 Year Clinigen Chart

1 Year Clinigen Chart

1 Month Clinigen Chart

1 Month Clinigen Chart

Your Recent History

Delayed Upgrade Clock